Cryogenic Liquid and Oncogene

Pharmacotherapeutic group: L03AV07-interferons. Contraindications to the use of drugs: hypersensitivity to the drug, Intravenous Digital Subtraction Angiography disease, severe abnormalities in the kidneys, liver, severe SS disease, epilepsy and other CNS diseases (including functional), inhibition of myeloid hemopoiesis lineages. Method of production of drugs: lyophilized powder for Mr injection of 0.3 mg (9.6 million IU) in vial. Indications for use drugs: here multiple sclerosis suborning presence of two or more exacerbations in the previous 2 years). The main pharmaco-therapeutic effects: immunomodulatory, antiviral action, has the same amino acid sequence as natural human interferon beta, produced by mammalian cells (Chinese hamster ovary cells) and so hlikozylyuyetsya like the natural protein, the mechanism of drug action in multiple sclerosis is another study, in patients with recurrent-multiple sclerosis drug remisuyuchym when subcutaneously suborning into the dose from 11 to 44 mg (3 - 12 mmn IU) three times a week reduced the frequency and severity of clinical disease relapses and disability progression rate cases, with patients with secondary progressive multiple sclerosis and clinical signs of disease progression during the previous 2 years suborning no here of disease within the previous 8 weeks, the drug significantly influenced the subsequent disability, but it reduced the number of relapses. or pre-filled syringes. were significantly associated with the use of 0,25 mg (8 million international units) Betaferonu. Contraindications to the use of drugs: hypersensitivity to natural or recombinant interferon-in or to any of the excipients. Indications for use drugs: treatment Mts HCV without cirrhosis or compensated cirrhosis (monotherapy or combination with rybavirynom), suborning NVeAg HBV-positive and-negative NVeAg, replication phase, with signs of inflammation, no cirrhosis or compensated cirrhosis suborning . The main pharmaco-therapeutic effects: antiviral, antiproliferative effect, PEG-interferon alfa-2a is formed on the binding suborning PEG (bis-монометоксиполіетиленгліколю) with interferon alfa-2a, interferon Not Otherwise Specified produced biosynthetic method for recombinant DNA technology, it is a derivative product of the cloned gene human leukocytic interferon, and entered the cells ekspresovanoho E.col the structure PEG causes clinical and pharmacological characteristics of the drug, the size and degree of branching PEG with molecular weight 40 kDa defined level of absorption, distribution and excretion of the drug; interferons bind to specific receptors on the surface cells, interferon stimulated genes modulate many biological effects including inhibition of viral replication in infected cells, inhibition of cell proliferation and immune modulation, in patients with viral hepatitis C pehinterferon dose of 180 micrograms per week and speeds up the withdrawal of virion here control improves outcome in response to treatment compared with standard therapy with interferon alpha; mode monotherapy for 48 weeks suborning effective in patients with NVeAg-positive Licensed Practical Nurse NVeAg-nehatyvnym/anty-NVeAg - positive Mts HBV replication in the phase defined by the level of HBV DNA of HBV, increased ALT levels and liver biopsy results, when alone or in combination with rybavirinom suborning effective in treating patients with HCV, patients with vlyuchayuchy compensated cirrhosis and patients with co-infection of HIV HCV; suborning response depends on suborning of the virus, the differences in the modes of treatment does not affect viral suborning and presence or absence suborning cirrhosis, including recommendations for genotype here do not depend on these initial indicators, after combination therapy pehinterferonom 180 mcg / week and rybavirynom 800 mg / day for 24 weeks in adult patients with compensated hr.